Preferences for managing GERD among HCPs and patients
Research type
Research Study
Full title
A study to examine preferences for the Management of gastroesophageal reflux disease (GERD): A mixed methods analysis among patients and HCPs, culminating in a discrete choice experiment
IRAS ID
318528
Contact name
Simon Leigh
Contact email
Sponsor organisation
Reckitt
Duration of Study in the UK
0 years, 7 months, days
Research summary
Proton-pump inhibitors (PPIs) remain the leading evidence-based therapy for upper gastrointestinal disorders, including gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease. However, treatment often becomes ongoing and difficult to suspend, leading to overutilization in multiple treatment arenas.
Aside from economic considerations, the elevated use of PPIs may additionally expose patients to an increasing number of potential risks while not always providing a therapeutic benefit to those receiving them.
The aims of this research are to understand the reasons behind long-term PPI use for those with GERD, from both a patient and HCP perspective, particularly among patients where a therapeutic benefit may not be experienced. Additionally, we aim to explore how we as a scientific community may work towards reducing potentially avoidable PPI prescribing, understanding the concerns of HCPs and patients, and examining the support that would be required in order to safely transition patients away from PPIs where a therapeutic benefit is limited or absent, and to understand the preferences of both patients and HCPs towards the management of GERD.
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
23/NW/0052
Date of REC Opinion
6 Jun 2023
REC opinion
Further Information Favourable Opinion